Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis
The prognosis of patients with combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma (CHC) is usually poor, and effective adjuvant therapy is missing making it important to investigate whether these patients may benefit from adjuvant transarterial chemoembolization (TACE). We aimed t...
Saved in:
| Published in | BMC cancer Vol. 20; no. 1; pp. 642 - 11 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
10.07.2020
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The prognosis of patients with combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma (CHC) is usually poor, and effective adjuvant therapy is missing making it important to investigate whether these patients may benefit from adjuvant transarterial chemoembolization (TACE). We aimed to evaluate the efficiency of adjuvant TACE for long-term recurrence and survival after curative resection before and after propensity score matching (PSM) analysis.
In this retrospective study, of 230 patients who underwent resection for CHC between January 1994 and December 2014, 46 (18.0%) patients received adjuvant TACE. Univariate and multivariate regression analyses were used to identify the independent predictive factors of survival. Cox regression analyses and log-rank tests were used to compare overall survival (OS) and disease-free survival (DFS) between patients who did or did not receive adjuvant TACE.
A total of 230 patients (mean age 52.2 ± 11.9 years; 172 men) were enrolled, and 46 (mean age 52.7 ± 11.1 years; 38 men) patients received TACE. Before PSM, in multivariate regression analysis, γ-glutamyl transpeptidase (γ-GT), tumour nodularity, macrovascular invasion (MVI), lymphoid metastasis, and extrahepatic metastasis were associated with OS. Alanine aminotransferase (ALT), MVI, lymphoid metastasis, and preventive TACE (HR: 2.763, 95% CI: 1.769-4.314, p < 0.001) were independent prognostic factors for DFS. PSM created 46 pairs of patients. Before PSM, adjuvant preventive TACE was not associated with an increased risk of OS (HR: 0.911, 95% CI: 0.545-1.520, p = 0.720) or DFS (HR: 3.345, 95% CI: 1.686-6.638, p = 0.001). After PSM, the 5-year OS and DFS rates were comparable in the TACE group and the non-TACE group (OS: 22.7% vs 14.9%, respectively, p = 0.75; DFS: 11.2% vs 14.4%, respectively, p = 0.06).
The present study identified that adjuvant preventive TACE did not influence DFS or OS after curative resection of CHC. |
|---|---|
| AbstractList | The prognosis of patients with combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma (CHC) is usually poor, and effective adjuvant therapy is missing making it important to investigate whether these patients may benefit from adjuvant transarterial chemoembolization (TACE). We aimed to evaluate the efficiency of adjuvant TACE for long-term recurrence and survival after curative resection before and after propensity score matching (PSM) analysis.
In this retrospective study, of 230 patients who underwent resection for CHC between January 1994 and December 2014, 46 (18.0%) patients received adjuvant TACE. Univariate and multivariate regression analyses were used to identify the independent predictive factors of survival. Cox regression analyses and log-rank tests were used to compare overall survival (OS) and disease-free survival (DFS) between patients who did or did not receive adjuvant TACE.
A total of 230 patients (mean age 52.2 ± 11.9 years; 172 men) were enrolled, and 46 (mean age 52.7 ± 11.1 years; 38 men) patients received TACE. Before PSM, in multivariate regression analysis, γ-glutamyl transpeptidase (γ-GT), tumour nodularity, macrovascular invasion (MVI), lymphoid metastasis, and extrahepatic metastasis were associated with OS. Alanine aminotransferase (ALT), MVI, lymphoid metastasis, and preventive TACE (HR: 2.763, 95% CI: 1.769-4.314, p < 0.001) were independent prognostic factors for DFS. PSM created 46 pairs of patients. Before PSM, adjuvant preventive TACE was not associated with an increased risk of OS (HR: 0.911, 95% CI: 0.545-1.520, p = 0.720) or DFS (HR: 3.345, 95% CI: 1.686-6.638, p = 0.001). After PSM, the 5-year OS and DFS rates were comparable in the TACE group and the non-TACE group (OS: 22.7% vs 14.9%, respectively, p = 0.75; DFS: 11.2% vs 14.4%, respectively, p = 0.06).
The present study identified that adjuvant preventive TACE did not influence DFS or OS after curative resection of CHC. Background The prognosis of patients with combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma (CHC) is usually poor, and effective adjuvant therapy is missing making it important to investigate whether these patients may benefit from adjuvant transarterial chemoembolization (TACE). We aimed to evaluate the efficiency of adjuvant TACE for long-term recurrence and survival after curative resection before and after propensity score matching (PSM) analysis. Methods In this retrospective study, of 230 patients who underwent resection for CHC between January 1994 and December 2014, 46 (18.0%) patients received adjuvant TACE. Univariate and multivariate regression analyses were used to identify the independent predictive factors of survival. Cox regression analyses and log-rank tests were used to compare overall survival (OS) and disease-free survival (DFS) between patients who did or did not receive adjuvant TACE. Results A total of 230 patients (mean age 52.2 [+ or -] 11.9 years; 172 men) were enrolled, and 46 (mean age 52.7 [+ or -] 11.1 years; 38 men) patients received TACE. Before PSM, in multivariate regression analysis, [gamma]-glutamyl transpeptidase ([gamma]-GT), tumour nodularity, macrovascular invasion (MVI), lymphoid metastasis, and extrahepatic metastasis were associated with OS. Alanine aminotransferase (ALT), MVI, lymphoid metastasis, and preventive TACE (HR: 2.763, 95% CI: 1.769-4.314, p < 0.001) were independent prognostic factors for DFS. PSM created 46 pairs of patients. Before PSM, adjuvant preventive TACE was not associated with an increased risk of OS (HR: 0.911, 95% CI: 0.545-1.520, p = 0.720) or DFS (HR: 3.345, 95% CI: 1.686-6.638, p = 0.001). After PSM, the 5-year OS and DFS rates were comparable in the TACE group and the non-TACE group (OS: 22.7% vs 14.9%, respectively, p = 0.75; DFS: 11.2% vs 14.4%, respectively, p = 0.06). Conclusions The present study identified that adjuvant preventive TACE did not influence DFS or OS after curative resection of CHC. Keywords: Combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma, Transarterial chemoembolization, Overall survival, Disease-free survival, Propensity score matching analysis The prognosis of patients with combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma (CHC) is usually poor, and effective adjuvant therapy is missing making it important to investigate whether these patients may benefit from adjuvant transarterial chemoembolization (TACE). We aimed to evaluate the efficiency of adjuvant TACE for long-term recurrence and survival after curative resection before and after propensity score matching (PSM) analysis. In this retrospective study, of 230 patients who underwent resection for CHC between January 1994 and December 2014, 46 (18.0%) patients received adjuvant TACE. Univariate and multivariate regression analyses were used to identify the independent predictive factors of survival. Cox regression analyses and log-rank tests were used to compare overall survival (OS) and disease-free survival (DFS) between patients who did or did not receive adjuvant TACE. A total of 230 patients (mean age 52.2 [+ or -] 11.9 years; 172 men) were enrolled, and 46 (mean age 52.7 [+ or -] 11.1 years; 38 men) patients received TACE. Before PSM, in multivariate regression analysis, [gamma]-glutamyl transpeptidase ([gamma]-GT), tumour nodularity, macrovascular invasion (MVI), lymphoid metastasis, and extrahepatic metastasis were associated with OS. Alanine aminotransferase (ALT), MVI, lymphoid metastasis, and preventive TACE (HR: 2.763, 95% CI: 1.769-4.314, p < 0.001) were independent prognostic factors for DFS. PSM created 46 pairs of patients. Before PSM, adjuvant preventive TACE was not associated with an increased risk of OS (HR: 0.911, 95% CI: 0.545-1.520, p = 0.720) or DFS (HR: 3.345, 95% CI: 1.686-6.638, p = 0.001). After PSM, the 5-year OS and DFS rates were comparable in the TACE group and the non-TACE group (OS: 22.7% vs 14.9%, respectively, p = 0.75; DFS: 11.2% vs 14.4%, respectively, p = 0.06). The present study identified that adjuvant preventive TACE did not influence DFS or OS after curative resection of CHC. The prognosis of patients with combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma (CHC) is usually poor, and effective adjuvant therapy is missing making it important to investigate whether these patients may benefit from adjuvant transarterial chemoembolization (TACE). We aimed to evaluate the efficiency of adjuvant TACE for long-term recurrence and survival after curative resection before and after propensity score matching (PSM) analysis.BACKGROUNDThe prognosis of patients with combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma (CHC) is usually poor, and effective adjuvant therapy is missing making it important to investigate whether these patients may benefit from adjuvant transarterial chemoembolization (TACE). We aimed to evaluate the efficiency of adjuvant TACE for long-term recurrence and survival after curative resection before and after propensity score matching (PSM) analysis.In this retrospective study, of 230 patients who underwent resection for CHC between January 1994 and December 2014, 46 (18.0%) patients received adjuvant TACE. Univariate and multivariate regression analyses were used to identify the independent predictive factors of survival. Cox regression analyses and log-rank tests were used to compare overall survival (OS) and disease-free survival (DFS) between patients who did or did not receive adjuvant TACE.METHODSIn this retrospective study, of 230 patients who underwent resection for CHC between January 1994 and December 2014, 46 (18.0%) patients received adjuvant TACE. Univariate and multivariate regression analyses were used to identify the independent predictive factors of survival. Cox regression analyses and log-rank tests were used to compare overall survival (OS) and disease-free survival (DFS) between patients who did or did not receive adjuvant TACE.A total of 230 patients (mean age 52.2 ± 11.9 years; 172 men) were enrolled, and 46 (mean age 52.7 ± 11.1 years; 38 men) patients received TACE. Before PSM, in multivariate regression analysis, γ-glutamyl transpeptidase (γ-GT), tumour nodularity, macrovascular invasion (MVI), lymphoid metastasis, and extrahepatic metastasis were associated with OS. Alanine aminotransferase (ALT), MVI, lymphoid metastasis, and preventive TACE (HR: 2.763, 95% CI: 1.769-4.314, p < 0.001) were independent prognostic factors for DFS. PSM created 46 pairs of patients. Before PSM, adjuvant preventive TACE was not associated with an increased risk of OS (HR: 0.911, 95% CI: 0.545-1.520, p = 0.720) or DFS (HR: 3.345, 95% CI: 1.686-6.638, p = 0.001). After PSM, the 5-year OS and DFS rates were comparable in the TACE group and the non-TACE group (OS: 22.7% vs 14.9%, respectively, p = 0.75; DFS: 11.2% vs 14.4%, respectively, p = 0.06).RESULTSA total of 230 patients (mean age 52.2 ± 11.9 years; 172 men) were enrolled, and 46 (mean age 52.7 ± 11.1 years; 38 men) patients received TACE. Before PSM, in multivariate regression analysis, γ-glutamyl transpeptidase (γ-GT), tumour nodularity, macrovascular invasion (MVI), lymphoid metastasis, and extrahepatic metastasis were associated with OS. Alanine aminotransferase (ALT), MVI, lymphoid metastasis, and preventive TACE (HR: 2.763, 95% CI: 1.769-4.314, p < 0.001) were independent prognostic factors for DFS. PSM created 46 pairs of patients. Before PSM, adjuvant preventive TACE was not associated with an increased risk of OS (HR: 0.911, 95% CI: 0.545-1.520, p = 0.720) or DFS (HR: 3.345, 95% CI: 1.686-6.638, p = 0.001). After PSM, the 5-year OS and DFS rates were comparable in the TACE group and the non-TACE group (OS: 22.7% vs 14.9%, respectively, p = 0.75; DFS: 11.2% vs 14.4%, respectively, p = 0.06).The present study identified that adjuvant preventive TACE did not influence DFS or OS after curative resection of CHC.CONCLUSIONSThe present study identified that adjuvant preventive TACE did not influence DFS or OS after curative resection of CHC. Background The prognosis of patients with combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma (CHC) is usually poor, and effective adjuvant therapy is missing making it important to investigate whether these patients may benefit from adjuvant transarterial chemoembolization (TACE). We aimed to evaluate the efficiency of adjuvant TACE for long-term recurrence and survival after curative resection before and after propensity score matching (PSM) analysis. Methods In this retrospective study, of 230 patients who underwent resection for CHC between January 1994 and December 2014, 46 (18.0%) patients received adjuvant TACE. Univariate and multivariate regression analyses were used to identify the independent predictive factors of survival. Cox regression analyses and log-rank tests were used to compare overall survival (OS) and disease-free survival (DFS) between patients who did or did not receive adjuvant TACE. Results A total of 230 patients (mean age 52.2 ± 11.9 years; 172 men) were enrolled, and 46 (mean age 52.7 ± 11.1 years; 38 men) patients received TACE. Before PSM, in multivariate regression analysis, γ-glutamyl transpeptidase (γ-GT), tumour nodularity, macrovascular invasion (MVI), lymphoid metastasis, and extrahepatic metastasis were associated with OS. Alanine aminotransferase (ALT), MVI, lymphoid metastasis, and preventive TACE (HR: 2.763, 95% CI: 1.769–4.314, p < 0.001) were independent prognostic factors for DFS. PSM created 46 pairs of patients. Before PSM, adjuvant preventive TACE was not associated with an increased risk of OS (HR: 0.911, 95% CI: 0.545–1.520, p = 0.720) or DFS (HR: 3.345, 95% CI: 1.686–6.638, p = 0.001). After PSM, the 5-year OS and DFS rates were comparable in the TACE group and the non-TACE group (OS: 22.7% vs 14.9%, respectively, p = 0.75; DFS: 11.2% vs 14.4%, respectively, p = 0.06). Conclusions The present study identified that adjuvant preventive TACE did not influence DFS or OS after curative resection of CHC. Abstract Background The prognosis of patients with combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma (CHC) is usually poor, and effective adjuvant therapy is missing making it important to investigate whether these patients may benefit from adjuvant transarterial chemoembolization (TACE). We aimed to evaluate the efficiency of adjuvant TACE for long-term recurrence and survival after curative resection before and after propensity score matching (PSM) analysis. Methods In this retrospective study, of 230 patients who underwent resection for CHC between January 1994 and December 2014, 46 (18.0%) patients received adjuvant TACE. Univariate and multivariate regression analyses were used to identify the independent predictive factors of survival. Cox regression analyses and log-rank tests were used to compare overall survival (OS) and disease-free survival (DFS) between patients who did or did not receive adjuvant TACE. Results A total of 230 patients (mean age 52.2 ± 11.9 years; 172 men) were enrolled, and 46 (mean age 52.7 ± 11.1 years; 38 men) patients received TACE. Before PSM, in multivariate regression analysis, γ-glutamyl transpeptidase (γ-GT), tumour nodularity, macrovascular invasion (MVI), lymphoid metastasis, and extrahepatic metastasis were associated with OS. Alanine aminotransferase (ALT), MVI, lymphoid metastasis, and preventive TACE (HR: 2.763, 95% CI: 1.769–4.314, p < 0.001) were independent prognostic factors for DFS. PSM created 46 pairs of patients. Before PSM, adjuvant preventive TACE was not associated with an increased risk of OS (HR: 0.911, 95% CI: 0.545–1.520, p = 0.720) or DFS (HR: 3.345, 95% CI: 1.686–6.638, p = 0.001). After PSM, the 5-year OS and DFS rates were comparable in the TACE group and the non-TACE group (OS: 22.7% vs 14.9%, respectively, p = 0.75; DFS: 11.2% vs 14.4%, respectively, p = 0.06). Conclusions The present study identified that adjuvant preventive TACE did not influence DFS or OS after curative resection of CHC. |
| ArticleNumber | 642 |
| Audience | Academic |
| Author | Zhou, Jian Zhou, Yu-Fu Jiang, Xi-Fei Fan, Jia Liu, Wei-Ren Tang, Zheng Tao, Chen-Yang Qu, Wei-Feng Shi, Ying-Hong Song, Shu-Shu Zhou, Pei-Yun Fang, Yuan Tian, Meng-Xin Wang, Han Ding, Zhen-Bin |
| Author_xml | – sequence: 1 givenname: Wei-Ren surname: Liu fullname: Liu, Wei-Ren – sequence: 2 givenname: Meng-Xin surname: Tian fullname: Tian, Meng-Xin – sequence: 3 givenname: Chen-Yang surname: Tao fullname: Tao, Chen-Yang – sequence: 4 givenname: Zheng surname: Tang fullname: Tang, Zheng – sequence: 5 givenname: Yu-Fu surname: Zhou fullname: Zhou, Yu-Fu – sequence: 6 givenname: Shu-Shu surname: Song fullname: Song, Shu-Shu – sequence: 7 givenname: Xi-Fei surname: Jiang fullname: Jiang, Xi-Fei – sequence: 8 givenname: Han surname: Wang fullname: Wang, Han – sequence: 9 givenname: Pei-Yun surname: Zhou fullname: Zhou, Pei-Yun – sequence: 10 givenname: Wei-Feng surname: Qu fullname: Qu, Wei-Feng – sequence: 11 givenname: Yuan surname: Fang fullname: Fang, Yuan – sequence: 12 givenname: Zhen-Bin surname: Ding fullname: Ding, Zhen-Bin – sequence: 13 givenname: Jian surname: Zhou fullname: Zhou, Jian – sequence: 14 givenname: Jia surname: Fan fullname: Fan, Jia – sequence: 15 givenname: Ying-Hong surname: Shi fullname: Shi, Ying-Hong |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32650743$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9k9tu1DAQhiNURA_wAlwgS0gILlJsJ5tke4FUVRwqVUKCcm1NnMnGK8de7GShfWIeg8luC7sVQrmwNf7nG_vPzHFy4LzDJHku-KkQVfE2CllVs5RLnvJSZFV6-yg5EnkpUpnz8mBnf5gcx7jkXJQVr54kh5ksZrzMs6Pk13mzHNfgBnYdwEUIAwYDlukOe4997a25hcF4xxqPkTk_MONaO6LTyALqMYRpm7YBkfnA_BoDWMviGNZmTSDj2IoA6IbIfpihY9r3tXHYsA7pwGu0drQQmIagjfM9MHANu-i8Bbcwfifc0t0YVSTceioeUU83O2PAVsGv0EUz3LCofUDWw6A74xYEA3sTTXyaPG7BRnx2t54k3z68v774lF59_nh5cX6V6kJWQ1rP61ILkLnEnGdFXQNoXc2KVmSYS2gr4KJo-ExqgY0sc8znNQIAb8usEYXITpLLLbfxsFSrYHoIN8qDUZuADwtFJhttUTVY1zjXbc7neV5XRZ1pLOcZosSSCwRivduyVmPdY6PJRDJ3D7p_4kynFn6tyox-76wgwOs7QPDfR4yD6k2cHAeHfoyKnpnxophXM5K-fCBd-jGQeRtVXhKy4H9VC6AHUCd4qqsnqDovMlHNJZeSVKf_UNHXYG80NXFrKL6X8GYvgTQD_hwWMMaoLr9-2de-2tF2CHboorfj1ApxX_hi170_tt03PwmqrUAHH2PAVmkzbJqdrmusElxNc6a2c6ZoztRmztQtpcoHqff0_yT9BgToMbA |
| CitedBy_id | crossref_primary_10_1097_JS9_0000000000000805 crossref_primary_10_1007_s00261_023_04089_4 crossref_primary_10_3389_fonc_2022_977111 crossref_primary_10_3389_fonc_2021_686972 crossref_primary_10_1016_j_ejso_2023_107279 crossref_primary_10_1007_s11912_022_01338_5 crossref_primary_10_1007_s13304_023_01648_8 crossref_primary_10_2147_CMAR_S361462 |
| Cites_doi | 10.1016/S0140-6736(02)08649-X 10.1002/lt.23897 10.3322/caac.21262 10.7150/jca.23921 10.1111/1475-6773.12182 10.7150/jca.23229 10.1016/j.dld.2017.01.166 10.1634/theoncologist.2014-0470 10.1002/hep.29789 10.1111/jgs.14253 10.1245/s10434-011-2150-0 10.1016/S1470-2045(15)00198-9 10.1111/j.1742-1241.2007.01694.x 10.1016/j.hepres.2005.04.003 10.1016/j.gassur.2006.01.018 10.1053/j.gastro.2015.02.055 10.1158/1078-0432.CCR-17-2899 10.4254/wjh.v9.i6.300 10.1371/journal.pone.0198138 10.1007/s00432-012-1343-7 10.1148/radiol.09091076 10.1007/s00432-006-0091-y 10.1016/j.amjsurg.2004.03.018 10.1200/JCO.2012.42.9936 10.1016/j.jhep.2018.03.019 10.1245/s10434-008-0278-3 10.1002/lt.24711 10.2307/2533160 10.1016/S0140-6736(17)33326-3 10.1245/s10434-012-2328-0 10.3748/wjg.v10.i19.2791 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2020 BioMed Central Ltd. 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2020 |
| Copyright_xml | – notice: COPYRIGHT 2020 BioMed Central Ltd. – notice: 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2020 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM ISR 3V. 7TO 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12885-020-07138-z |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Science ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) Medical Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2407 |
| EndPage | 11 |
| ExternalDocumentID | oai_doaj_org_article_debbe9cf40944b86b3ce793ee2e701ea PMC7350756 A631892022 32650743 10_1186_s12885_020_07138_z |
| Genre | Journal Article |
| GeographicLocations | United States--US |
| GeographicLocations_xml | – name: United States--US |
| GrantInformation_xml | – fundername: National Natural Science Foundation of China grantid: 81773067 – fundername: National Natural Science Foundation of China grantid: 81502486 – fundername: ; grantid: 81502486; 81773067 |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACMJI ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR IHW INH INR ISR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS U2A UKHRP W2D WOQ WOW XSB CGR CUY CVF ECM EIF NPM PMFND 3V. 7TO 7XB 8FK AZQEC DWQXO H94 K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c628t-b9b7c1a242e4036bbaacc856f13e42af8a016d052c1ed274e49beaaa0f73d1613 |
| IEDL.DBID | 7X7 |
| ISSN | 1471-2407 |
| IngestDate | Wed Aug 27 01:22:27 EDT 2025 Thu Aug 21 18:40:49 EDT 2025 Thu Jul 10 23:00:27 EDT 2025 Fri Jul 25 19:55:50 EDT 2025 Tue Jun 17 21:55:42 EDT 2025 Tue Jun 10 20:12:31 EDT 2025 Fri Jun 27 03:35:10 EDT 2025 Thu May 22 21:21:45 EDT 2025 Thu Apr 03 06:56:34 EDT 2025 Tue Jul 01 04:28:56 EDT 2025 Thu Apr 24 22:59:45 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma Overall survival Propensity score matching analysis Transarterial chemoembolization Disease-free survival |
| Language | English |
| License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c628t-b9b7c1a242e4036bbaacc856f13e42af8a016d052c1ed274e49beaaa0f73d1613 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://www.proquest.com/docview/2424773560?pq-origsite=%requestingapplication% |
| PMID | 32650743 |
| PQID | 2424773560 |
| PQPubID | 44074 |
| PageCount | 11 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_debbe9cf40944b86b3ce793ee2e701ea pubmedcentral_primary_oai_pubmedcentral_nih_gov_7350756 proquest_miscellaneous_2423066985 proquest_journals_2424773560 gale_infotracmisc_A631892022 gale_infotracacademiconefile_A631892022 gale_incontextgauss_ISR_A631892022 gale_healthsolutions_A631892022 pubmed_primary_32650743 crossref_citationtrail_10_1186_s12885_020_07138_z crossref_primary_10_1186_s12885_020_07138_z |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-07-10 |
| PublicationDateYYYYMMDD | 2020-07-10 |
| PublicationDate_xml | – month: 07 year: 2020 text: 2020-07-10 day: 10 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | BMC cancer |
| PublicationTitleAlternate | BMC Cancer |
| PublicationYear | 2020 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | DH Jung (7138_CR12) 2017; 23 WT Kassahun (7138_CR30) 2008; 62 ZG Ren (7138_CR27) 2004; 10 J Li (7138_CR29) 2015; 20 JH Kim (7138_CR31) 2010; 255 JH Lee (7138_CR26) 2015; 148 P Magistri (7138_CR11) 2017; 49 DH Kim (7138_CR23) 2016; 64 JM Llovet (7138_CR17) 2002; 359 MM Garrido (7138_CR24) 2014; 49 SK Na (7138_CR19) 2018; 13 LA Torre (7138_CR1) 2015; 65 S Gera (7138_CR5) 2017; 9 KC Koh (7138_CR13) 2005; 189 ZW Peng (7138_CR18) 2013; 31 DB Rubin (7138_CR22) 1996; 52 S Ariizumi (7138_CR10) 2012; 19 HC Sun (7138_CR20) 2006; 132 European Association for the Study of the Liver (7138_CR21) 2018; 69 KH Kim (7138_CR9) 2009; 16 Z Wang (7138_CR16) 2018; 24 C Allemani (7138_CR2) 2018; 391 D Tang (7138_CR14) 2006; 10 Y Sanada (7138_CR15) 2005; 32 J Bruix (7138_CR25) 2015; 16 M Garancini (7138_CR3) 2014; 20 E Brunt (7138_CR4) 2018; 68 CY Tao (7138_CR8) 2018; 9 MX Tian (7138_CR6) 2018; 9 X Yin (7138_CR7) 2012; 19 X Chen (7138_CR28) 2013; 139 |
| References_xml | – volume: 359 start-page: 1734 issue: 9319 year: 2002 ident: 7138_CR17 publication-title: Lancet doi: 10.1016/S0140-6736(02)08649-X – volume: 20 start-page: 952 issue: 8 year: 2014 ident: 7138_CR3 publication-title: Liver Transpl doi: 10.1002/lt.23897 – volume: 65 start-page: 87 issue: 2 year: 2015 ident: 7138_CR1 publication-title: CA Cancer J Clin doi: 10.3322/caac.21262 – volume: 9 start-page: 1106 issue: 6 year: 2018 ident: 7138_CR8 publication-title: J Cancer doi: 10.7150/jca.23921 – volume: 49 start-page: 1701 issue: 5 year: 2014 ident: 7138_CR24 publication-title: Health Serv Res doi: 10.1111/1475-6773.12182 – volume: 9 start-page: 1025 issue: 6 year: 2018 ident: 7138_CR6 publication-title: J Cancer doi: 10.7150/jca.23229 – volume: 49 start-page: 467 issue: 5 year: 2017 ident: 7138_CR11 publication-title: Digest Liver Dis doi: 10.1016/j.dld.2017.01.166 – volume: 20 start-page: 640 issue: 6 year: 2015 ident: 7138_CR29 publication-title: Oncologist doi: 10.1634/theoncologist.2014-0470 – volume: 68 start-page: 113 issue: 1 year: 2018 ident: 7138_CR4 publication-title: Hepatology doi: 10.1002/hep.29789 – volume: 64 start-page: 2065 issue: 10 year: 2016 ident: 7138_CR23 publication-title: J Am Geriatr Soc doi: 10.1111/jgs.14253 – volume: 19 start-page: 1628 issue: 5 year: 2012 ident: 7138_CR10 publication-title: Ann Surg Oncol doi: 10.1245/s10434-011-2150-0 – volume: 16 start-page: 1344 issue: 13 year: 2015 ident: 7138_CR25 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(15)00198-9 – volume: 62 start-page: 1271 issue: 8 year: 2008 ident: 7138_CR30 publication-title: Int J Clin Pract doi: 10.1111/j.1742-1241.2007.01694.x – volume: 32 start-page: 185 issue: 3 year: 2005 ident: 7138_CR15 publication-title: Hepatol Res doi: 10.1016/j.hepres.2005.04.003 – volume: 10 start-page: 987 issue: 7 year: 2006 ident: 7138_CR14 publication-title: J Gastrointest Surg doi: 10.1016/j.gassur.2006.01.018 – volume: 148 start-page: 1383 issue: 7 year: 2015 ident: 7138_CR26 publication-title: Gastroenterology doi: 10.1053/j.gastro.2015.02.055 – volume: 24 start-page: 2074 issue: 9 year: 2018 ident: 7138_CR16 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-17-2899 – volume: 9 start-page: 300 issue: 6 year: 2017 ident: 7138_CR5 publication-title: World J Hepatol doi: 10.4254/wjh.v9.i6.300 – volume: 13 start-page: e0198138 issue: 6 year: 2018 ident: 7138_CR19 publication-title: PLoS One doi: 10.1371/journal.pone.0198138 – volume: 139 start-page: 773 issue: 5 year: 2013 ident: 7138_CR28 publication-title: J Cancer Res Clin Oncol doi: 10.1007/s00432-012-1343-7 – volume: 255 start-page: 270 issue: 1 year: 2010 ident: 7138_CR31 publication-title: Radiology doi: 10.1148/radiol.09091076 – volume: 132 start-page: 458 issue: 7 year: 2006 ident: 7138_CR20 publication-title: J Cancer Res Clin Oncol doi: 10.1007/s00432-006-0091-y – volume: 189 start-page: 120 issue: 1 year: 2005 ident: 7138_CR13 publication-title: Am J Surg doi: 10.1016/j.amjsurg.2004.03.018 – volume: 31 start-page: 426 issue: 4 year: 2013 ident: 7138_CR18 publication-title: J Clin Oncol doi: 10.1200/JCO.2012.42.9936 – volume: 69 start-page: 182 issue: 1 year: 2018 ident: 7138_CR21 publication-title: J Hepatol doi: 10.1016/j.jhep.2018.03.019 – volume: 16 start-page: 623 issue: 3 year: 2009 ident: 7138_CR9 publication-title: Ann Surg Oncol doi: 10.1245/s10434-008-0278-3 – volume: 23 start-page: 330 issue: 3 year: 2017 ident: 7138_CR12 publication-title: Liver Transpl doi: 10.1002/lt.24711 – volume: 52 start-page: 249 issue: 1 year: 1996 ident: 7138_CR22 publication-title: Biometrics doi: 10.2307/2533160 – volume: 391 start-page: 1023 issue: 10125 year: 2018 ident: 7138_CR2 publication-title: Lancet doi: 10.1016/S0140-6736(17)33326-3 – volume: 19 start-page: 2869 issue: 9 year: 2012 ident: 7138_CR7 publication-title: Ann Surg Oncol doi: 10.1245/s10434-012-2328-0 – volume: 10 start-page: 2791 issue: 19 year: 2004 ident: 7138_CR27 publication-title: World J Gastroenterol doi: 10.3748/wjg.v10.i19.2791 |
| SSID | ssj0017808 |
| Score | 2.3641264 |
| Snippet | The prognosis of patients with combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma (CHC) is usually poor, and effective adjuvant therapy is... Background The prognosis of patients with combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma (CHC) is usually poor, and effective adjuvant... Abstract Background The prognosis of patients with combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma (CHC) is usually poor, and effective... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 642 |
| SubjectTerms | Alanine Alanine transaminase Analysis Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bile Duct Neoplasms - mortality Bile Duct Neoplasms - pathology Bile Duct Neoplasms - therapy Biliary tract cancer Cancer metastasis Carcinoma, Hepatocellular - mortality Carcinoma, Hepatocellular - pathology Carcinoma, Hepatocellular - therapy Care and treatment Chemoembolization Chemoembolization, Therapeutic - mortality Chemotherapy, Adjuvant Cholangiocarcinoma Cholangiocarcinoma - mortality Cholangiocarcinoma - pathology Cholangiocarcinoma - therapy Combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma Combined Modality Therapy Disease-free survival Female Follow-Up Studies Hepatectomy - mortality Hepatocellular carcinoma Humans Liver cancer Liver Neoplasms - mortality Liver Neoplasms - pathology Liver Neoplasms - therapy Lymphatic system Male Medical prognosis Medical research Metastases Metastasis Middle Aged Neoplasm Recurrence, Local - mortality Neoplasm Recurrence, Local - pathology Neoplasm Recurrence, Local - therapy Overall survival Patient outcomes Prognosis Propensity score matching analysis Regression analysis Retrospective Studies Surgery Survival Survival Rate Transarterial chemoembolization Transplants & implants Tumors Veins & arteries γ-Glutamyltransferase |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEF6hHhAXxBtDgQEhcUBWHT_Wa26hoipIcAAq9bbaXc-2qRK7ip1LfzE_g5m1E8VCggtXexzH629mvvHOQ4i3pfQVIul35Sof567MY5XWjohcTQiyJftkzrb4Jk_P8i_nxfneqC_OCRvaAw8Ld1SjtVg5z3FIbpW0mUPCFGKKZTLDQI3I522DqXH_oFSJ2pbIKHnUkRVWXImccMEOqfjNxA2Fbv1_2uQ9pzRNmNzzQCf3xN2ROsJ8-Mv3xS1sHojbX8fN8Yfi17y-2hAx7iE4oJCsSegCei2rFle2XY41l1C32EHT9rDYjiiBNX93D5V_sV8jQrsGTu40yyV0GzInBEiShrENawf8_RYIrRRYYw2X5NT6ljcBOKsVHA8oatqVAdPUcMzhc3OxaPcO82RyoDuGtuPAJVChvuIDGLjm7YGGU0Wg4x6bQJw6JHzSjw0NVB6Js5NPP49P43GQQ-xkqvrYVrZ0M0NsAHPymNYa45wqpJ9lmKfGK0PEs06K1M2wpjAZ88qiMSbxZVYTJc0ei4OmbfCpgKxGk1g_886QXzVFZVCirHwmVWYTbyIx275X7cYu5zxsY6lDtKOkHrCgCQs6YEHfROL97prrocfHX6U_Mlx2ktyfOxwg1OoRtfpfqI3EKwabHopdd1ZGzyVpSJUSsYrEmyDBPToaTgK6MJuu059_fJ8IvRuFfEtP6cxYU0FrxW29JpKHE0kyIm56eot6PRqxTnPlUFlmxIkj8Xp3mq_kxLwG202QoaBTVqqIxJNBSXYrQ5FBwQw1EuVEfSZLNz3TLC5Di3O6K3FZ-ex_rPVzcScdNJ84x6E46NcbfEFMsrcvg9H4DSJper8 priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9RAEF9qBfFF_DZadRXBB4nmc7MRRM5iqUJ9UAt9W3Y3k-vJXVKTHGj_Yv8MZzbJecHS1-zsJTeZj99k54OxF5kocwDU79zmpZ_YLPFlVFgEcgVKkMnIJ1O2xRdxeJx8PklPdtg47mhgYHthaEfzpI6b5etfP3-_R4V_5xReijct2lhJdcYBleOgAp9fYVfRM2U00eAo-XeqkMlAjoUzF-6bOCfXw_9_S73lqqZplFt-6eAmuzEASj7rJeAW24HqNrt2NByZ32F_ZsWPNcLljju35FI4UeY4vqxVDStTL4dKTF7U0PKq7vhiHFzCG_oa7-oB_bIB4HXDKeVTL5e8XaORQTFFaj40Z205fdXlKMMYbkPBT9HVdTUdDVCuK7c0tqiqV5rrquD7xPlqvqi3LtO8co53dM3IORVGuaqLt1zzMzo0qCiBhLfUeZMj0nZpoPhjfVuVu-z44OP3_UN_GO_gWxHJzje5yWyoESNAgn7UGK2tlakowxiSSJdSIxwtgjSyIRQYPEOSG9BaB2UWFwhU43tst6oreMB4XIAOTBmWVqO31WmuQYDIy1jI2ASl9lg4vldlh97nNIJjqVwMJIXqZUGhLCgnC-rcY682e876zh-XUn8gcdlQUtdud6Fu5mowAqoAYyC3JcXUiZHCxBbQPgJEkAUh4GM-JWFTfQnsxvaomUC9ySOEWx577iioc0dFqUFzvW5b9enb1wnRy4GorPFfWj1UWiCvqNnXhHJvQommxU6XR6lXo2YqqifKshiRsseebZZpJ6XrVVCvHQ2GoiKXqcfu90qy4QzGCynhVo9lE_WZsG66Ui1OXeNzvCsiXPHw8sd6xK5HvU4jxthju12zhseIHDvzxJmDvw6GdA4 priority: 102 providerName: Scholars Portal |
| Title | Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/32650743 https://www.proquest.com/docview/2424773560 https://www.proquest.com/docview/2423066985 https://pubmed.ncbi.nlm.nih.gov/PMC7350756 https://doaj.org/article/debbe9cf40944b86b3ce793ee2e701ea |
| Volume | 20 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdgkxAviG8KoxiExAOKlq86Di9onTYNpE1oMKnixbKdS1fUxaNpX_YX82dw57ilEdJe8hBfmtS-T_vud4y9L0RdAqB8l7aso9wWeSTTyqIjVyEHmYJsMmVbnImTi_zrZDQJG25tSKtc60SvqCtnaY98n8oYiiJDA_35-ndEXaPodDW00LjLdgm6jLi6mGwCrqSQsVwXykix36IullSPHFPZDgr6Tc8Yecz-_zXzlmnqp01u2aHjh-xBcCD5Qbfij9gdaB6ze6fhiPwJ-3NQ_Vqhe7zk3gz5lE3kMY6Lc-Xgyrh5qLzklYOWN27JZ-tGJXxBu---_i-qFwDcLTileOr5nLcrVCrIlkjNAxhry2kXl-P8YXgNFb9E07Z0dBRAua3cUpuixl1prpuKH1IQ3Uxnbus29Sfn-EYPPs6pEMpXWXziml_TIUFDCSO8JaRNjp61T_vEH-tgVJ6yi-OjH4cnUWjnEFmRymVkSlPYRONCQo520xitrZUjUScZ5KmupUb3s4pHqU2gwmAZ8tKA1jqui6xCxzR7xnYa18ALxrMKdGzqpLYaraselRoEiLLOhMxMXOsBS9brqmzAOqeWG3PlYx4pVMcLCnlBeV5QNwP2cfPMdYf0cSv1mNhlQ0ko3f6GW0xVEHpVgTFQ2ppi6NxIYTILqA8BUijiBPAz3xCzqa7kdaNr1IFAOSlTdK8G7J2nIKSOhlKBpnrVturL9_Me0YdAVDv8l1aHygqcKwL36lHu9ShRldj-8JrrVVBlrfoneAP2djNMT1J6XgNu5Wkw9BSlHA3Y805INjOD8cGI_NQBK3ri05u6_kgzu_RA5_hW9GjFy9s_6xW7n3YyjT7FHttZLlbwGj3FpRl6dTBku-Ojs2_nQ7_fgtfTXOL1fPzzL9qddRM |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkYAL4s1CoQaBOKCoea2TICG0FKpd-jhAK_Xm2s6kXbQbL5tdIfqj-F38DGacZGmE1Fuv8eRlz3wzY8-DsVeJKDIAlO_MZIUXmyT20jA3aMjlyEE6IZ1M0RYHYngUfznuH6-x320uDIVVtpjogDq3hvbItyiNIUkiVNAfZj886hpFp6ttC42aLXbh10902ar3o0-4vq_DcOfz4fbQa7oKeEaE6cLTmU5MoPB5ECN8a62UMWlfFEEEcaiKVKEVlPv90ASQo88GcaZBKeUXSZSjfRThc6-x66h4fXL2kuOVgxckqZ-2iTmp2KoQ-1PKf_YpTQiB5byj_FyPgP81wQVV2A3TvKD3du6w243Bygc1h91la1DeYzf2myP5--zPIP--RHN8wZ3acyGiyNMcmWFqYartpMn05LmFipd2wcdtYxQ-p91-l2_oFXMAbuecQkrVZMKrJYIYigFS86b4a8Vp15jjeqE7Dzk_Q1W6sHT0QLG03FBbpNJOFVdlzrfJaS9Px_bCZeqHzvGNrtg5p8Qrl9Xxjis-o0OJkgJUeEWVPTla8i7MFB9Wl215wI6uZKEfsvXSlvCY8SgH5esiKIxCba76mQIBIisikUbaL1SPBe26StPUVqcWHxPpfKxUyJoXJPKCdLwgz3vs7eqeWV1Z5FLqj8QuK0qqCu4u2PmpbEBG5qA1ZKYgnz3WqdCRAcRfgBASPwD8zE1iNlmn2K6wTQ4EymUWojnXYy8dBVUGKSn06FQtq0qOvn3tEL1piAqLf2lUk8mBc0XFxDqUGx1KhC7THW65XjbQWcl_gt5jL1bDdCeFA5Zgl44GXV2Rpf0ee1QLyWpm0B_pk13cY0lHfDpT1x0px2eusDq-FS1o8eTyz9pkN4eH-3tyb3Sw-5TdCmv5Rntmg60v5kt4hlbqQj930MDZyVVj0V8BU65u |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Adjuvant+Transarterial+chemoembolization+does+not+influence+recurrence-free+or+overall+survival+in+patients+with+combined+hepatocellular+carcinoma+and+Cholangiocarcinoma+after+curative+resection%3A+a+propensity+score+matching+analysis&rft.jtitle=BMC+cancer&rft.au=Wei-Ren%2C+Liu&rft.au=Meng-Xin%2C+Tian&rft.au=Chen-Yang%2C+Tao&rft.au=Tang%2C+Zheng&rft.date=2020-07-10&rft.pub=BioMed+Central&rft.eissn=1471-2407&rft.volume=20&rft.spage=1&rft_id=info:doi/10.1186%2Fs12885-020-07138-z |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2407&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2407&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2407&client=summon |